Myriad Genetics beats Street

Myriad Genetics Inc. (NASDAQ:MYGN) reported fiscal 2Q10 diluted EPS from continuing operations of $0.36, beating the Street's estimate of $0.34 but down from $0.38 in fiscal 2Q09. Fiscal second quarter revenues were up 11% to $92.8 million from $84 million for the prior year's quarter. Costs and expenses rose 15% to $58.2 million. In July, Myriad Genetics spun out its drug development business into Myriad Pharmaceuticals Inc. (NASDAQ:MYRX).

Myriad Genetics also said Greg Critchfield will retire as president of its Myriad Genetic Laboratories subsidiary, effective March 1. He will be replaced by Mark Capone, currently COO of the subsidiary. Myriad Genetics, which made the announcement after market close, was up $0.20 to $23.98 on Tuesday. ...